At the news
? MIXEDIMPACT 6/10 8-K filed Aug 13, 2026 at 16:02 ET
FocalTherics (FOCL) reported strong Q2 2026 HIFU continuing operations revenue of $13.2M (+39% YoY), with 13 Focal One system sales (+44% YoY) and 47% US procedure growth. However, the net loss widened to $14.4M ($0.38 loss per share) from $6.4M ($0.17 loss) due to a $5.5M EIB warrant valuation charge, and the company announced a $40M dilutive public offering. Management reiterated full-year 2026 revenue guidance of $50-54M (34-45% YoY growth).
- HIFU continuing operations revenue rose 39% YoY to $13.2M (Q2 2026 vs Q2 2025: $9.5M); consensus was $15.1M.
- 13 Focal One capital system sales in Q2 2026 vs 9 in prior year period, including 2 lease conversions (+44% YoY).
- Gross margin improved to 55.6% from 51.1% YoY.
- Net loss from continuing operations was $14.4M ($0.38/share) vs $6.4M ($0.17/share) in Q2 2025, the increase was primarily due to a $5.5M loss from change in fair value of warrant liability.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access